Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Janet E Pope^{1

2}

Affiliations

¹ Division of Rheumatology, St Joseph's Health Care, London, Ontario, Canada. janet.pope@sjhc.london.on.ca.
² Department of Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. janet.pope@sjhc.london.on.ca.

Comment

Janet E Pope. Nat Rev Rheumatol. 2023 Oct.

. 2023 Oct;19(10):676.

doi: 10.1038/s41584-023-01014-3.

Janet E Pope^{1

2}

¹ Division of Rheumatology, St Joseph's Health Care, London, Ontario, Canada. janet.pope@sjhc.london.on.ca.
² Department of Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. janet.pope@sjhc.london.on.ca.

No abstract available

Comment on

State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. Pope JE, et al. Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27. Nat Rev Rheumatol. 2023. PMID: 36849541 Free PMC article. Review.
Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
Andréasson K, Hamberg V, Wigén J, Westergren-Thorsson G. Andréasson K, et al. Nat Rev Rheumatol. 2023 Oct;19(10):675. doi: 10.1038/s41584-023-01013-4. Nat Rev Rheumatol. 2023. PMID: 37605003 No abstract available.

1. Pope, J. E. et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat. Rev. Rheumatol. 19, 212–226 (2023). - DOI - PubMed - PMC
1. Andréasson, K. et al. Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading? Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-023-01013-4 (2023). - DOI - PubMed
1. Nambiar, A. M., Anzueto, A. R. & Peters, J. I. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. PLoS ONE 12, e0176312 (2017). - DOI - PubMed - PMC
1. Wigén, J., Elowsson-Rendin, L., Karlsson, L., Tykesson, E. & Westergren-Thorsson, G. Glycosaminoglycans: a link between development and regeneration in the lung. Stem Cells Dev. 28, 823–832 (2019). - DOI - PubMed
1. Lescoat, A. et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem. Pharmacol. 178, 114103 (2020). - DOI - PubMed